Question 1

What is AAV-hAQP1?

Accepted Answer

AAV-hAQP1 is a Other.

Question 2

How often does AAV-hAQP1 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was AAV-hAQP1 first tracked by Ergen?

Accepted Answer

First tracked on Apr 14, 2026.

Question 4

When was AAV-hAQP1 last mentioned in news?

Accepted Answer

Last active on Apr 16, 2026.

Question 5

What is AAV-hAQP1's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AAV-hAQP1 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AAV-hAQP1?

Accepted Answer

MeiraGTx AAV-hAQP1 3-Year Data (Apr 14, 2026, 6 articles).

Question 8

How did the "MeiraGTx AAV-hAQP1 3-Year Data" event impact AAV-hAQP1?

Accepted Answer

AAV-hAQP1 is the investigational gene therapy developed by MeiraGTx that showed positive three-year data in the Phase 1 AQUAx study for radiation-induced xerostomia.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.